Low Barthel index score is a poor prognostic factor for newly diagnosed multiple myeloma patients

被引:2
|
作者
Geng, Chuanying [1 ]
Yang, Guangzhong [1 ]
Zhou, Huixing [1 ]
Wang, Huijuan [1 ]
Li, Yanchen [1 ]
Leng, Yun [1 ]
Zhang, Zhiyao [1 ]
Jian, Yuan [1 ]
Chen, Wenming [1 ]
机构
[1] Capital Med Univ, Beijing Chaoyang Hosp, Dept Hematol, Beijing 100020, Peoples R China
关键词
Multiple myeloma; Barthel index; Survival; Prognostic factors; GERIATRIC-ASSESSMENT; CRITERIA; FRAILTY;
D O I
10.1007/s10238-023-01002-7
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The basic activities of daily life may affect the prognosis of multiple myeloma (MM) patients and the Barthel index (BI) is currently the most widely used tool to evaluate basic activities of daily life, but few studies have evaluated its prognostic value in MM. We retrospectively enrolled patients with newly diagnosed MM and analyzed the association between the BI and the survival of newly diagnosed MM patients. We totally analyzed 538 patients and found that median overall survival (OS) and progression-free survival (PFS) were significantly shorter in the low BI (<= 85) group compared with the high BI (> 85) group. Univariate Cox proportional hazards regression analysis showed that the low BI was associated with shorter OS and PFS. It was also confirmed that the low BI was poor prognostic factor for OS and PFS in multivariable analyses. In the propensity score matching analysis, patients with low BI also had shorter OS and PFS. Our study suggested that the low BI was a poor prognostic factor for patients with newly diagnosed MM.
引用
收藏
页码:2593 / 2600
页数:8
相关论文
共 50 条
  • [31] Absolute lymphocyte count as a prognostic marker in newly diagnosed multiple myeloma patients
    Suriu, C.
    Akria, L.
    Azoulay, D.
    Shaoul, E.
    Barhoum, M.
    Braester, A.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2016, 38 (03) : e56 - e59
  • [32] The prognostic significance of circulating plasma cells in newly diagnosed multiple myeloma patients
    Yao, Weiqin
    Yang, Haifei
    You, Hongying
    Shang, Jingjing
    Zhai, Yingying
    Yan, Zhi
    Yan, Shuang
    Shi, Xiaolan
    Yao, Ying
    Wang, Jing
    Wang, Panfeng
    Xu, Yun
    Jin, Song
    Yan, Lingzhi
    Wu, Depei
    Fu, Chengcheng
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [33] CD43 Expression Is an Adverse Prognostic Factor in Newly Diagnosed Multiple Myeloma
    Ning, Xueqin
    Wei, Yongqiang
    Wei, Xiaolei
    Feng, Ru
    Chen, Bingyuan
    Yi, Zhengshan
    Zheng, Zhongxin
    BLOOD, 2021, 138
  • [34] Lymphopenia predicts poor outcomes in newly diagnosed multiple myeloma
    Ferri, Grace M.
    Yildirim, Cenk
    Do, Nhan, V
    Brophy, Mary
    Park, Joseph S.
    Munshi, Nikhil C.
    Fillmore, Nathanael R.
    V. Edwards, Camille
    BLOOD ADVANCES, 2025, 9 (01)
  • [35] Extreme body mass index and survival in newly diagnosed multiple myeloma patients
    Shah, Urvi A. A.
    Whiting, Karissa
    Devlin, Sean
    Ershler, Rachel
    Kanapuru, Bindu
    Lee, David J. J.
    Tahri, Sabrin
    Gwise, Thomas
    Rustad, Even H. H.
    Mailankody, Sham
    Lesokhin, Alexander M. M.
    Kazandjian, Dickran
    Maura, Francesco
    Auclair, Daniel
    Birmann, Brenda M. M.
    Usmani, Saad Z. Z.
    Gormley, Nicole
    Marinac, Catherine R. R.
    Landgren, Ola
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [36] Extreme body mass index and survival in newly diagnosed multiple myeloma patients
    Urvi A. Shah
    Karissa Whiting
    Sean Devlin
    Rachel Ershler
    Bindu Kanapuru
    David J. Lee
    Sabrin Tahri
    Thomas Gwise
    Even H. Rustad
    Sham Mailankody
    Alexander M. Lesokhin
    Dickran Kazandjian
    Francesco Maura
    Daniel Auclair
    Brenda M. Birmann
    Saad Z. Usmani
    Nicole Gormley
    Catherine R. Marinac
    Ola Landgren
    Blood Cancer Journal, 13
  • [37] Body Mass Index and Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
    Wang, Bei
    Derman, Benjamin A.
    Langerman, Spencer S.
    Johnson, Julie
    Zhang, Wei
    Jakubowiak, Andrzej
    Chiu, Brian C-H
    CANCERS, 2022, 14 (21)
  • [38] Serum Platelet Factor 4 Is a Promising Therapeutic Response and Prognostic Marker in Patients with Newly Diagnosed Multiple Myeloma
    Bai, Ju
    He, Aili
    Zhang, Wanggang
    Yang, Yun
    Wang, Jianli
    Zhang, Pengyu
    Zhang, Yang
    Zhang, Lei
    Gu, Liufang
    Wang, Jin
    Shi, Rui
    Meng, Xin
    Tian, Wei
    Wang, Xiaman
    Lei, Xiaoru
    BLOOD, 2014, 124 (21)
  • [39] Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies
    Zagouri, Flora
    Kastritis, Efstathios
    Zomas, Athanasios
    Terpos, Evangelos
    Katodritou, Eirini
    Symeonidis, Argiris
    Delimpasi, Sosana
    Pouli, Anastasia
    Vassilakopoulos, Theodoros P.
    Michalis, Eurydiki
    Giannouli, Stavroula
    Kartasis, Zafiris
    Christoforidou, Anna
    Kokoviadou, Kiriaki
    Hatzimichael, Eleftheria
    Gika, Dimitra
    Megalakaki, Catherine
    Papaioannou, Maria
    Kyrtsonis, Marie-Christine
    Konstantopoulos, Kostas
    Dimopoulos, Meletios A.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 99 (05) : 409 - 414
  • [40] Evaluation of serum Cystatin-C as a prognostic and predictive factor in patients with newly diagnosed multiple myeloma.
    Reddy, Rakesh
    Gupta, Ritu
    Mathur, Nitin
    Rani, Lata
    Sharma, Atul
    Kumar, Lalit
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)